You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMecamylamine
Accession NumberDB00657  (APRD00458)
TypeSmall Molecule
GroupsApproved
DescriptionA nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. [PubChem]
Structure
Thumb
Synonyms
Versamine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mecamylamine HydrochlorideTablet2.5 mg/1OralNexgen Pharma, Inc.2013-03-19Not applicableUs
VecamylTablet2.5 mg/1OralManchester Pharmaceuticals2013-03-19Not applicableUs
VecamylTablet2.5 mg/1OralTuring Pharmaceuticals2013-03-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
InversineTargacept
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mecamylamine hydrochloride
Thumb
  • InChI Key: PKVZBNCYEICAQP-UHFFFAOYNA-N
  • Monoisotopic Mass: 203.144077416
  • Average Mass: 203.752
DBSALT000652
Categories
UNII6EE945D3OK
CAS number60-40-2
WeightAverage: 167.2911
Monoisotopic: 167.167399677
Chemical FormulaC11H21N
InChI KeyIMYZQPCYWPFTAG-UHFFFAOYSA-N
InChI
InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3
IUPAC Name
N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
SMILES
CNC1(C)C2CCC(C2)C1(C)C
Pharmacology
IndicationFor the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension
Structured Indications
PharmacodynamicsMecamylamine is a potent, oral antihypertensive agent and ganglion blocker, and is a secondary amine. Mecamylamine is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. Mecamylamine reduces blood pressure in both normotensive and hypertensive individuals. A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced. Mecamylamine crosses the blood-brain and placental barriers.
Mechanism of actionMecamylamine is a ganglionic blocker which prevents stimulation of postsynaptic receptors by acetylcholine released from presynaptic nerve endings. The hypotensive effect of Mecamylamine is attributed to reduction in sympathetic tone, vasodilation, and reduced cardiac output, and is primarily postural.
TargetKindPharmacological actionActionsOrganismUniProt ID
Neuronal acetylcholine receptor subunit alpha-2Proteinyes
inhibitor
HumanQ15822 details
Related Articles
AbsorptionMecamylamine is almost completely absorbed from the gastrointestinal tract
Volume of distributionNot Available
Protein binding40%
MetabolismNot Available
Route of eliminationMecamylamine is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine. Mecamylamine crosses the blood-brain and placental barriers.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINEThe risk or severity of adverse effects can be increased when 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE is combined with Mecamylamine.Experimental
1,10-PhenanthrolineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Mecamylamine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Acetazolamide.Approved, Vet Approved
AclarubicinAclarubicin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
AclidiniumAclidinium may increase the anticholinergic activities of Mecamylamine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mecamylamine.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Mecamylamine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Alphacetylmethadol.Experimental, Illicit
AlprenololMecamylamine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
Aluminum hydroxideThe serum concentration of Mecamylamine can be increased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Mecamylamine can be increased when it is combined with Aluminum phosphate.Approved
AmbenoniumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ambenonium.Approved
AmbrisentanMecamylamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineMecamylamine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmikacinAmikacin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Mecamylamine.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Mecamylamine.Approved
Ammonium chlorideThe serum concentration of Mecamylamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Mecamylamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Amphotericin B.Approved, Investigational
AmrubicinAmrubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Amyl Nitrite.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Mecamylamine.Approved
annamycinannamycin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Apraclonidine.Approved
ApramycinApramycin may increase the neuromuscular blocking activities of Mecamylamine.Experimental, Vet Approved
ArbekacinArbekacin may increase the neuromuscular blocking activities of Mecamylamine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Mecamylamine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Mecamylamine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Mecamylamine.Approved, Vet Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Azilsartan medoxomil.Approved
AzosemideThe risk or severity of adverse effects can be increased when Azosemide is combined with Mecamylamine.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Mecamylamine.Experimental
BarbitalBarbital may increase the hypotensive activities of Mecamylamine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Barnidipine.Approved
BenactyzineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mecamylamine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mecamylamine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Mecamylamine.Withdrawn
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Mecamylamine.Approved
BenzthiazideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Mecamylamine.Approved
BepridilMecamylamine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Mecamylamine.Approved
BethanidineBethanidine may increase the hypotensive activities of Mecamylamine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BimatoprostMecamylamine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Biperiden.Approved
Bismuth SubcitrateThe serum concentration of Mecamylamine can be increased when it is combined with Bismuth Subcitrate.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Mecamylamine.Approved
BortezomibThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Mecamylamine.Approved, Investigational
Botulinum Toxin Type AMecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BMecamylamine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BretyliumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Mecamylamine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Mecamylamine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Mecamylamine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bupivacaine.Approved, Investigational
BupranololMecamylamine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Butorphanol.Approved, Illicit, Vet Approved
Calcium carbonateThe serum concentration of Mecamylamine can be increased when it is combined with Calcium carbonate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Candesartan.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Mecamylamine.Experimental
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Carfentanil.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Mecamylamine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Mecamylamine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Carvedilol.Approved, Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mecamylamine.Approved, Investigational
CeliprololMecamylamine may increase the hypotensive activities of Celiprolol.Approved, Investigational
Chloramine-TThe risk or severity of adverse effects can be increased when Chloramine-T is combined with Mecamylamine.Vet Approved
Chloroquinoxaline SulfonamideThe risk or severity of adverse effects can be increased when Chloroquinoxaline Sulfonamide is combined with Mecamylamine.Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mecamylamine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Chlorpromazine.Approved, Vet Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mecamylamine.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Cilnidipine.Approved
CimetropiumMecamylamine may increase the anticholinergic activities of Cimetropium.Experimental
ClevidipineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Mecamylamine.Approved
ClorsulonThe risk or severity of adverse effects can be increased when Clorsulon is combined with Mecamylamine.Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
ConivaptanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Conivaptan.Approved, Investigational
CoumaphosThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Coumaphos.Vet Approved
CryptenamineMecamylamine may increase the hypotensive activities of Cryptenamine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Cyclopentolate.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Cyclothiazide is combined with Mecamylamine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dapagliflozin.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Mecamylamine.Approved, Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Mecamylamine.Approved
DaunorubicinDaunorubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
DebrisoquinMecamylamine may increase the hypotensive activities of Debrisoquin.Approved
DecamethoniumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Mecamylamine.Approved
DeserpidineMecamylamine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Desflurane.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dexetimide.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mecamylamine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dezocine.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Diazoxide is combined with Mecamylamine.Approved
DichlorvosThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Dichlorvos.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Mecamylamine.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dicyclomine.Approved
DihydralazineMecamylamine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the neuromuscular blocking activities of Mecamylamine.Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Mecamylamine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dipyridamole.Approved
DonepezilThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Donepezil.Approved
DorzolamideMecamylamine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Mecamylamine.Approved
DoxorubicinDoxorubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Mecamylamine is combined with DPDPE.Investigational
DronabinolMecamylamine may increase the tachycardic activities of Dronabinol.Approved, Illicit
DuloxetineMecamylamine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EchothiophateThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Edrophonium.Approved
EfonidipineMecamylamine may increase the hypotensive activities of Efonidipine.Approved
EluxadolineMecamylamine may increase the constipating activities of Eluxadoline.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mecamylamine.Approved, Vet Approved
EnalaprilatMecamylamine may increase the hypotensive activities of Enalaprilat.Approved
EpirubicinEpirubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Eplerenone.Approved
EpoprostenolMecamylamine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Mecamylamine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etacrynic acid.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Mecamylamine.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Mecamylamine.Withdrawn
EthylmorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etorphine.Illicit, Vet Approved
FelodipineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Felodipine.Approved, Investigational
FenoldopamMecamylamine may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fimasartan.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mecamylamine.Approved
FramycetinFramycetin may increase the neuromuscular blocking activities of Mecamylamine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Mecamylamine.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Mecamylamine.Approved
GeneticinGeneticin may increase the neuromuscular blocking activities of Mecamylamine.Experimental
GentamicinGentamicin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the neuromuscular blocking activities of Mecamylamine.Experimental
Ginkgo bilobaThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Glucagon recombinant.Approved
GlycopyrroniumMecamylamine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Mecamylamine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Mecamylamine.Approved
GuanethidineMecamylamine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hexamethonium.Experimental
HexamethylenetetramineThe serum concentration of Mecamylamine can be decreased when it is combined with Hexamethylenetetramine.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Mecamylamine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Huperzine A.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Mecamylamine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Mecamylamine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Mecamylamine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydromorphone.Approved, Illicit
HYDROXYFASUDILThe risk or severity of adverse effects can be increased when HYDROXYFASUDIL is combined with Mecamylamine.Experimental
Hygromycin BHygromycin B may increase the neuromuscular blocking activities of Mecamylamine.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mecamylamine.Approved
IdarubicinIdarubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
IloprostIloprost may increase the hypotensive activities of Mecamylamine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Mecamylamine.Approved
IndenololMecamylamine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminMecamylamine may increase the hypotensive activities of Indoramin.Withdrawn
INNO-206INNO-206 may increase the neuromuscular blocking activities of Mecamylamine.Investigational
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mecamylamine.Approved
IproclozideIproclozide may increase the hypotensive activities of Mecamylamine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Mecamylamine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Mecamylamine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Mecamylamine.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Mecamylamine.Investigational
KanamycinKanamycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
KetanserinMecamylamine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ketobemidone.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Mecamylamine.Approved
LacidipineMecamylamine may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Mecamylamine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Mecamylamine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levobupivacaine.Approved
LevodopaMecamylamine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Lisinopril.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Lofentanil.Illicit
LofexidineMecamylamine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Losartan.Approved
MacitentanMecamylamine may increase the hypotensive activities of Macitentan.Approved
MafenideThe risk or severity of adverse effects can be increased when Mafenide is combined with Mecamylamine.Approved, Vet Approved
MagaldrateThe serum concentration of Mecamylamine can be increased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium oxide.Approved
Magnesium TrisilicateThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineMecamylamine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Mecamylamine.Withdrawn
MefloquineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Memantine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Mecamylamine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mecamylamine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Mecamylamine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Mecamylamine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Mecamylamine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Metipranolol.Approved
MetixeneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Mecamylamine.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Mecamylamine.Approved, Investigational
MetrizamideMetrizamide may increase the neuromuscular blocking activities of Mecamylamine.Approved
MetyrosineMecamylamine may increase the hypotensive activities of Metyrosine.Approved
MianserinMianserin may increase the anticholinergic activities of Mecamylamine.Approved
MibefradilMecamylamine may increase the hypotensive activities of Mibefradil.Withdrawn
MinaprineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Mecamylamine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mirabegron.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Mecamylamine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Mecamylamine.Approved
MorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Morphine.Approved, Investigational
MoxonidineMecamylamine may increase the hypotensive activities of Moxonidine.Approved
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneMecamylamine may increase the tachycardic activities of Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nadolol.Approved
NaftopidilMecamylamine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nalbuphine.Approved
NeamineNeamine may increase the neuromuscular blocking activities of Mecamylamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nebivolol.Approved, Investigational
NeomycinNeomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nesiritide.Approved, Investigational
NetilmicinNetilmicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
NialamideNialamide may increase the hypotensive activities of Mecamylamine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Mecamylamine.Approved
NicorandilNicorandil may increase the hypotensive activities of Mecamylamine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nifedipine.Approved
NiguldipineMecamylamine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMecamylamine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Mecamylamine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Mecamylamine.Approved
NitrendipineMecamylamine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Mecamylamine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Normethadone.Approved, Illicit
NVA237The risk or severity of adverse effects can be increased when Mecamylamine is combined with NVA237.Investigational
ObinutuzumabMecamylamine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Mecamylamine.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mecamylamine.Approved, Investigational
OmapatrilatMecamylamine may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Orphenadrine.Approved
OxprenololMecamylamine may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Mecamylamine.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Paclitaxel.Approved, Vet Approved
PancuroniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Mecamylamine.Approved
ParomomycinParomomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Mecamylamine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Mecamylamine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Mecamylamine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Mecamylamine.Approved
PhenoxybenzamineMecamylamine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Mecamylamine.Withdrawn
PhentolamineMecamylamine may increase the hypotensive activities of Phentolamine.Approved
PhysostigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Physostigmine.Approved
PinacidilMecamylamine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pipamperone.Approved
PipazethateThe risk or severity of adverse effects can be increased when Pipazethate is combined with Mecamylamine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pipecuronium.Approved
PirarubicinPirarubicin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Piritramide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Mecamylamine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Mecamylamine.Withdrawn
PlicamycinPlicamycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Mecamylamine.Approved
Potassium ChlorideMecamylamine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pramipexole.Approved, Investigational
PramlintidePramlintide may increase the anticholinergic activities of Mecamylamine.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Mecamylamine.Approved
PrimidonePrimidone may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Mecamylamine.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Mecamylamine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Mecamylamine.Approved, Investigational
PuromycinPuromycin may increase the neuromuscular blocking activities of Mecamylamine.Experimental
PyridostigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Pyridostigmine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quinapril.Approved, Investigational
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Mecamylamine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Mecamylamine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mecamylamine.Approved
RamosetronMecamylamine may increase the constipating activities of Ramosetron.Approved
RasagilineRasagiline may increase the hypotensive activities of Mecamylamine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Mecamylamine.Approved
RescinnamineMecamylamine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mecamylamine.Approved
RibostamycinRibostamycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
RilmenidineMecamylamine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Riociguat.Approved
RisperidoneMecamylamine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabMecamylamine may increase the hypotensive activities of Rituximab.Approved
RivastigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ropivacaine.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Rosuvastatin is combined with Mecamylamine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Mecamylamine.Withdrawn
SaprisartanMecamylamine may increase the hypotensive activities of Saprisartan.Experimental
ScopolamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine butylbromide.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Mecamylamine.Approved, Investigational
SelegilineSelegiline may increase the hypotensive activities of Mecamylamine.Approved, Investigational, Vet Approved
SelexipagMecamylamine may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Mecamylamine.Approved, Investigational
Silver sulfadiazineThe risk or severity of adverse effects can be increased when Silver sulfadiazine is combined with Mecamylamine.Approved, Vet Approved
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Mecamylamine.Approved
SisomicinSisomicin may increase the neuromuscular blocking activities of Mecamylamine.Investigational
SitaxentanMecamylamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Sodium Nitrite.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Solifenacin.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Mecamylamine.Approved
SP1049CSP1049C may increase the neuromuscular blocking activities of Mecamylamine.Investigational
SpectinomycinSpectinomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
SpiraprilMecamylamine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Mecamylamine.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Streptokinase.Approved
StreptomycinStreptomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
StreptozocinStreptozocin may increase the neuromuscular blocking activities of Mecamylamine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil.Approved, Investigational
SulfacetamideThe risk or severity of adverse effects can be increased when Sulfacetamide is combined with Mecamylamine.Approved
SulfachlorpyridazineThe risk or severity of adverse effects can be increased when Sulfachlorpyridazine is combined with Mecamylamine.Vet Approved
SulfacytineThe risk or severity of adverse effects can be increased when Sulfacytine is combined with Mecamylamine.Approved
SulfadiazineThe risk or severity of adverse effects can be increased when Sulfadiazine is combined with Mecamylamine.Approved, Vet Approved
SulfadimethoxineThe risk or severity of adverse effects can be increased when Sulfadimethoxine is combined with Mecamylamine.Approved, Vet Approved
SulfadoxineThe risk or severity of adverse effects can be increased when Sulfadoxine is combined with Mecamylamine.Approved
SulfaethoxypyridazineThe risk or severity of adverse effects can be increased when Sulfaethoxypyridazine is combined with Mecamylamine.Vet Approved
SulfamerazineThe risk or severity of adverse effects can be increased when Sulfamerazine is combined with Mecamylamine.Approved, Vet Approved
SulfameterThe risk or severity of adverse effects can be increased when Sulfameter is combined with Mecamylamine.Approved
SulfamethazineThe risk or severity of adverse effects can be increased when Sulfamethazine is combined with Mecamylamine.Approved, Vet Approved
SulfamethizoleThe risk or severity of adverse effects can be increased when Sulfamethizole is combined with Mecamylamine.Approved, Vet Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Mecamylamine.Approved
SulfametopyrazineThe risk or severity of adverse effects can be increased when Sulfametopyrazine is combined with Mecamylamine.Approved, Withdrawn
SulfamoxoleThe risk or severity of adverse effects can be increased when Sulfamoxole is combined with Mecamylamine.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine.Approved
SulfanitranThe risk or severity of adverse effects can be increased when Sulfanitran is combined with Mecamylamine.Vet Approved
SulfaphenazoleThe risk or severity of adverse effects can be increased when Sulfaphenazole is combined with Mecamylamine.Approved
SulfapyridineThe risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine.Approved
SulfaquinoxalineThe risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Mecamylamine.Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mecamylamine.Approved
SulfathiazoleThe risk or severity of adverse effects can be increased when Sulfathiazole is combined with Mecamylamine.Approved, Vet Approved
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Mecamylamine.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Mecamylamine.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Mecamylamine.Approved, Investigational
TacrineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Tacrine.Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Mecamylamine.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tapentadol.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Telmisartan.Approved, Investigational
TemocaprilMecamylamine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Terazosin.Approved
TerlipressinMecamylamine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetracyclineTetracycline may increase the neuromuscular blocking activities of Mecamylamine.Approved, Vet Approved
ThalidomideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Mecamylamine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Thioridazine.Approved
TiboloneMecamylamine may increase the hypotensive activities of Tibolone.Approved
TicrynafenMecamylamine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Mecamylamine.Approved
TiotropiumMecamylamine may increase the anticholinergic activities of Tiotropium.Approved
TizanidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tizanidine.Approved
TobramycinTobramycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
TolazolineMecamylamine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypotensive activities of Mecamylamine.Approved
TolterodineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Mecamylamine.Approved
TramadolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tramadol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mecamylamine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Mecamylamine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Mecamylamine.Approved
TravoprostTravoprost may increase the hypotensive activities of Mecamylamine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Mecamylamine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Mecamylamine.Approved
TrichlorfonThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Mecamylamine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mecamylamine.Approved
TrimazosinMecamylamine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Trimethaphan.Approved
TropicamideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tropicamide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Mecamylamine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Mecamylamine.Approved, Investigational
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Mecamylamine.Approved
UnoprostoneMecamylamine may increase the hypotensive activities of Unoprostone.Approved
ValrubicinValrubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mecamylamine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Mecamylamine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Verapamil.Approved
VinpocetineMecamylamine may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineMecamylamine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Mecamylamine.Approved, Vet Approved
ZorubicinZorubicin may increase the neuromuscular blocking activities of Mecamylamine.Experimental
Food InteractionsNot Available
References
Synthesis Reference

U.S. Patent 2,831,027.

General ReferencesNot Available
External Links
ATC CodesC02BB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9566
Blood Brain Barrier+0.9771
Caco-2 permeable+0.611
P-glycoprotein substrateNon-substrate0.6815
P-glycoprotein inhibitor INon-inhibitor0.8271
P-glycoprotein inhibitor IINon-inhibitor0.889
Renal organic cation transporterNon-inhibitor0.7727
CYP450 2C9 substrateNon-substrate0.7864
CYP450 2D6 substrateNon-substrate0.7207
CYP450 3A4 substrateSubstrate0.5884
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9054
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7435
Ames testNon AMES toxic0.9315
CarcinogenicityNon-carcinogens0.8757
BiodegradationNot ready biodegradable0.6954
Rat acute toxicity2.3843 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9676
hERG inhibition (predictor II)Non-inhibitor0.8756
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Targacept inc
Packagers
Dosage forms
FormRouteStrength
TabletOral2.5 mg/1
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point249 with decompositionU.S. Patent 2,831,027.
boiling point72 °C at 4.00E+00 mm HgPhysProp
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.124 mg/mLALOGPS
logP3.13ALOGPS
logP2.37ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)10.88ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity51.83 m3·mol-1ChemAxon
Polarizability20.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassMonoterpenoids
Direct ParentBicyclic monoterpenoids
Alternative Parents
Substituents
  • Bicyclic monoterpenoid
  • Cyclohexylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Struthers AM, Wilkinson JL, Dwoskin LP, Crooks PA, Bevins RA: Mecamylamine, dihydro-beta-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine. Pharmacol Biochem Behav. 2009 Dec;94(2):319-28. doi: 10.1016/j.pbb.2009.09.012. Epub 2009 Sep 22. [PubMed:19778551 ]
  5. Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR: Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7. [PubMed:12080428 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23